Skip to main content

Advertisement

Table 6 Impact of expression of PD-L1 on disease-free and overall survival tested by log-rank analysis

From: Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

Parameters Number of patients /recurrence/death Disease-free survival Overall survival
Mean survival (95 % CI) months p value Mean survival (95 % CI) months p value
PD-L1 (28-8) (T)    N/A   0.967
 Negative 191/16/17 N/A   91 (87–95)  
 Positive 27/0/2 N/A   59 (54–64)  
PD-L1 (E1L3N) (T)    N/A   0.647
 Negative 186/16/17 N/A   90 (86–95)  
 Positive 32/0/2 N/A   91 (84–98)  
PD-L1 (28-8) (I)    0.043   0.021
 Negative 138/14/17 89 (84–93)   87 (82–92)  
 Positive 80/2/2 97 (94–100)   97 (94–100)  
PD-L1 (E1L3N) (I)    0.761   0.255
 Negative 136/11/15 91 (87–95)   88 (84–93)  
 Positive 82/5/4 94 (89–98)   95 (90–99)  
PD-L1 (SP142) (I)    0.191   0.387
 Negative 176/15/17 90 (86–94)   89 (85–93)  
 Positive 42/1/2 97 (93–101)   95 (89–100)  
  1. Italics represents p < 0.05
  2. T tumor cell, I immune cell